Empty AAV2 capsids lacking the transgene of interest cause unwanted immune response without providing the therapeutic benefit of the transgene. Alongside DNA and infectious titer, determination of the capsid titer is crucial for validating the efficacy and safety of your AAV gene therapy. Our titration kit detects full and empty AAV9 capsids.